Published in Rev Infect Dis on August 16, 1989
Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A (1994) 7.76
Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol (2002) 4.63
An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol (2000) 4.00
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 3.06
Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 2.73
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med (2009) 2.59
Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol (2000) 2.49
Heterologous immunity between viruses. Immunol Rev (2010) 2.20
Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis (2002) 2.17
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol (1998) 2.03
Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol (2001) 1.92
Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis (2007) 1.88
Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS One (2009) 1.82
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol (2000) 1.79
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol (2001) 1.73
Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One (2009) 1.72
Demonstration of binding of dengue virus envelope protein to target cells. J Virol (1996) 1.60
Animal models of dengue virus infection. Viruses (2012) 1.60
Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev (2014) 1.55
Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol (2007) 1.52
Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol (1997) 1.49
Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication. J Biol Chem (2011) 1.45
Evaluation of nonstructural 1 antigen assays for the diagnosis and surveillance of dengue in Singapore. Vector Borne Zoonotic Dis (2010) 1.42
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol (2006) 1.34
A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis (2013) 1.33
Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun (2000) 1.30
Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol (1997) 1.29
Impact of renal failure on the outcome of dengue viral infection. Clin J Am Soc Nephrol (2008) 1.28
Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones. J Virol (1996) 1.28
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One (2007) 1.25
The four serotypes of dengue recognize the same putative receptors in Aedes aegypti midgut and Ae. albopictus cells. BMC Microbiol (2006) 1.25
Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol (1996) 1.22
Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol (2007) 1.20
Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol (2000) 1.18
TRAIL is a novel antiviral protein against dengue virus. J Virol (2007) 1.17
Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop Dis (2012) 1.14
Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol (1999) 1.14
Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J Virol (2000) 1.13
Dengue virus selectively induces human mast cell chemokine production. J Virol (2002) 1.12
Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol (2005) 1.11
Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine (2008) 1.11
Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res (2008) 1.09
Zika virus productively infects primary human placenta-specific macrophages. JCI Insight (2016) 1.04
B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis (2011) 1.04
Understanding the dengue viruses and progress towards their control. Biomed Res Int (2013) 1.02
Dengue virus infection induces upregulation of GRP78, which acts to chaperone viral antigen production. J Virol (2009) 1.01
Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity (2011) 0.98
Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability. Am J Physiol Lung Cell Mol Physiol (2009) 0.98
Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol (1997) 0.98
Zika Virus RNA Replication and Persistence in Brain and Placental Tissue. Emerg Infect Dis (2017) 0.96
Lung in dengue: computed tomography findings. PLoS One (2014) 0.96
Inhibition of dengue virus entry and multiplication into monocytes using RNA interference. PLoS Negl Trop Dis (2011) 0.94
Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl Trop Dis (2014) 0.94
The burden of dengue and chikungunya worldwide: implications for the southern United States and California. Ann Glob Health (2015) 0.93
Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis. Nat Rev Microbiol (2013) 0.91
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Maturation of dengue virus nonstructural protein 4B in monocytes enhances production of dengue hemorrhagic fever-associated chemokines and cytokines. Virology (2011) 0.85
Current perspectives on the spread of dengue in India. Infect Drug Resist (2014) 0.84
Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency. PLoS One (2008) 0.84
RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells. PLoS One (2012) 0.84
Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo. PLoS Negl Trop Dis (2013) 0.83
The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome. Virulence (2013) 0.83
A birth cohort study of viral infections in Vietnamese infants and children: study design, methods and characteristics of the cohort. BMC Public Health (2013) 0.83
Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo. Antimicrob Agents Chemother (2012) 0.82
Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis (2012) 0.81
Dengue 2 infection of HepG2 liver cells results in endoplasmic reticulum stress and induction of multiple pathways of cell death. BMC Res Notes (2013) 0.80
Re-evaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection. J Biomed Sci (2013) 0.80
The relevance of dengue virus genotypes surveillance at country level before vaccine approval. Hum Vaccin Immunother (2014) 0.80
Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISA. PLoS Negl Trop Dis (2013) 0.79
Elevated levels of full-length and thrombin-cleaved osteopontin during acute dengue virus infection are associated with coagulation abnormalities. Thromb Res (2014) 0.79
Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus. Am J Trop Med Hyg (2012) 0.78
Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol (2012) 0.78
SHP-1-dependent macrophage differentiation exacerbates virus-induced myositis. J Immunol (2015) 0.77
Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice. Med Microbiol Immunol (2014) 0.76
Elevated levels of vascular endothelial growth factor in adults with severe dengue infection. Virusdisease (2016) 0.75
Involvement of fatty acid synthase in dengue virus infection. Virol J (2017) 0.75
Epidemiology of Dengue Among Children Aged < 18 Months-Puerto Rico, 1999-2011. Am J Trop Med Hyg (2015) 0.75
Low sensitivity of the tourniquet test for differential diagnosis of dengue: an analysis of 28,000 trials in patients. BMC Infect Dis (2016) 0.75
Induction of Osteopontin by Dengue Virus-3 Infection in THP-1 Cells: Inhibition of the Synthesis by Brefelamide and Its Derivative. Front Microbiol (2017) 0.75
Delayed antibody dependent enhancement of low passage dengue virus 4 isolates. BMC Res Notes (2015) 0.75
Describing the breakbone fever: IDODEN, an ontology for dengue fever. PLoS Negl Trop Dis (2015) 0.75
Fcγ-receptor IIa-mediated Src Signaling Pathway is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection. PLoS Pathog (2016) 0.75
Dengue Virus-Induced Inflammation of the Endothelium and the Potential Roles of Sphingosine Kinase-1 and MicroRNAs. Mediators Inflamm (2015) 0.75
Bovine Lactoferrin Inhibits Dengue Virus Infectivity by Interacting with Heparan Sulfate, Low-Density Lipoprotein Receptor, and DC-SIGN. Int J Mol Sci (2017) 0.75